Grace Therapeutics Maintains Nasdaq Listing, Compliance Status
Ticker: GRCE · Form: 10-K · Filed: Jun 23, 2025 · CIK: 1444192
| Field | Detail |
|---|---|
| Company | Grace Therapeutics, INC. (GRCE) |
| Form Type | 10-K |
| Filed Date | Jun 23, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: Pharmaceuticals, SEC Filings, 10-K, Regulatory Compliance, Smaller Reporting Company, Nasdaq, Biotechnology
Related Tickers: GRCE
TL;DR
**GRCE's 10-K confirms regulatory compliance, but the lack of financial specifics makes it a 'wait and see' for any real investment thesis.**
AI Summary
Grace Therapeutics, Inc. (GRCE) reported its 10-K for the fiscal year ended March 31, 2025, indicating its status as a non-accelerated filer and a smaller reporting company. The company's common stock, with a par value of $0.0001 per share, is traded on the Nasdaq Stock Market under the symbol GRCE. Grace Therapeutics, Inc. has filed all required reports under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and has been subject to such filing requirements for the past 90 days. The company also confirmed electronic submission of every Interactive Data File required by Rule 405 of Regulation S-T during the preceding 12 months. The filing does not provide specific revenue or net income figures, nor does it detail key business changes or strategic outlook, focusing instead on its regulatory compliance and filing status. Risks are not explicitly detailed in the provided excerpt.
Why It Matters
For investors, Grace Therapeutics' continued compliance with SEC filing requirements and its Nasdaq listing under GRCE provides a baseline of operational transparency and market access. Its status as a non-accelerated and smaller reporting company suggests a lower market capitalization and potentially higher volatility compared to larger pharmaceutical peers. This competitive context means GRCE may face greater challenges in securing funding and attracting institutional investors, impacting its ability to develop new pharmaceutical preparations. Employees and customers are indirectly affected by the company's financial health and ability to innovate, which are not detailed here.
Risk Assessment
Risk Level: medium — The risk level is medium because while Grace Therapeutics, Inc. has demonstrated compliance with SEC filing requirements and maintains its Nasdaq listing, the provided excerpt lacks crucial financial data such as revenue, net income, or specific operational risks. This absence of detailed financial performance and forward-looking statements makes it difficult to fully assess the company's health and future prospects, creating uncertainty for investors.
Analyst Insight
Investors should hold off on making any significant moves based solely on this 10-K excerpt. Further due diligence is required to review the full filing for detailed financial statements, operational performance, and strategic plans before considering an investment in GRCE.
Key Numbers
- $0.0001 — Common Stock Par Value (This is the par value per share for GRCE's common stock, indicating a nominal value.)
- 10-K — Form Type (This is the annual report filed with the SEC for the fiscal year ended March 31, 2025.)
- 001-35776 — SEC File Number (This unique identifier is used by the SEC for Grace Therapeutics, Inc.'s filings.)
- March 31, 2025 — Fiscal Year End (This date marks the end of the reporting period for this 10-K filing.)
- 2025-06-23 — Filed As Of Date (This is the date the 10-K was officially filed with the SEC.)
Key Players & Entities
- Grace Therapeutics, Inc. (company) — registrant of the 10-K filing
- Nasdaq Stock Market (regulator) — exchange where GRCE Common Stock is registered
- SEC (regulator) — governing body for 10-K filings
- $0.0001 (dollar_amount) — par value per share of Common Stock
- March 31, 2025 (date) — fiscal year end for the 10-K report
- 001-35776 (regulator) — Commission file number for Grace Therapeutics, Inc.
- 103 Carnegie Center Suite 300 Princeton, New Jersey 08540 (company) — business address of Grace Therapeutics, Inc.
- 609-322-1602 (company) — telephone number of Grace Therapeutics, Inc.
- Acasti Pharma Inc. (company) — former name of Grace Therapeutics, Inc.
- August 28, 2008 (date) — date of name change from Acasti Pharma Inc. to Grace Therapeutics, Inc.
FAQ
What is Grace Therapeutics, Inc.'s fiscal year end?
Grace Therapeutics, Inc.'s fiscal year ends on March 31, as indicated by the 'CONFORMED PERIOD OF REPORT: 20250331' in the 10-K filing.
Is Grace Therapeutics, Inc. a well-known seasoned issuer?
No, Grace Therapeutics, Inc. is not a well-known seasoned issuer, as explicitly marked 'No' in the 10-K filing under Rule 405 of the Securities Act.
On which exchange is Grace Therapeutics, Inc. common stock traded?
Grace Therapeutics, Inc.'s Common Stock, par value $0.0001 per share, is traded on the Nasdaq Stock Market under the trading symbol GRCE.
Has Grace Therapeutics, Inc. filed all required reports in the last 12 months?
Yes, Grace Therapeutics, Inc. has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months.
What is the par value of Grace Therapeutics, Inc.'s common stock?
The par value of Grace Therapeutics, Inc.'s common stock is $0.0001 per share, as stated in the 'Title of each class' section of the 10-K.
What is Grace Therapeutics, Inc.'s SEC file number?
Grace Therapeutics, Inc.'s Commission file number is 001-35776, as listed on the cover page of the 10-K filing.
Is Grace Therapeutics, Inc. considered a large accelerated filer?
No, Grace Therapeutics, Inc. is not a large accelerated filer; it is marked as a 'Non-accelerated filer' and a 'Smaller reporting company' in the 10-K.
What was the former name of Grace Therapeutics, Inc.?
The former name of Grace Therapeutics, Inc. was Acasti Pharma Inc., with the name change occurring on August 28, 2008.
Where is Grace Therapeutics, Inc.'s principal executive office located?
Grace Therapeutics, Inc.'s principal executive office is located at 103 Carnegie Center, Suite 300, Princeton, New Jersey 08540.
Has Grace Therapeutics, Inc. submitted all required Interactive Data Files?
Yes, Grace Therapeutics, Inc. has submitted electronically every Interactive Data File required pursuant to Rule 405 of Regulation S-T during the preceding 12 months.
Industry Context
Grace Therapeutics, Inc. operates within the pharmaceutical preparations sector (SIC code 2834). This industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition from both established pharmaceutical giants and emerging biotechnology firms. Success often hinges on innovation, intellectual property protection, and effective clinical trial execution.
Regulatory Implications
As a pharmaceutical company, Grace Therapeutics, Inc. is subject to stringent oversight by regulatory bodies like the FDA. Compliance with Good Manufacturing Practices (GMP), clinical trial regulations, and post-market surveillance is critical. The company's status as a non-accelerated and smaller reporting company may influence the scope of its regulatory disclosures, but core compliance remains paramount.
What Investors Should Do
- Seek additional financial disclosures
- Monitor upcoming filings for business updates
- Research industry peers for comparative analysis
Key Dates
- 2025-03-31: Fiscal Year End — Marks the end of the reporting period for the 10-K filing.
- 2025-06-23: 10-K Filing Date — The date Grace Therapeutics, Inc. officially submitted its annual report to the SEC.
Glossary
- 10-K
- An annual report required by the U.S. Securities and Exchange Commission (SEC) that gives a comprehensive summary of a company's financial performance. (This document is the primary source of detailed financial and operational information for Grace Therapeutics, Inc. for the fiscal year ended March 31, 2025.)
- Non-accelerated filer
- A category of filer defined by the SEC based on public float, indicating a company that does not meet the criteria for accelerated or large accelerated filer status. (Grace Therapeutics, Inc. is classified as a non-accelerated filer, which may imply certain reporting requirements or flexibility compared to larger filers.)
- Smaller reporting company
- A designation by the SEC for companies with a public float below a certain threshold, allowing for scaled disclosure requirements. (Grace Therapeutics, Inc. qualifies as a smaller reporting company, suggesting its financial disclosures might be less extensive than those of larger entities.)
- Par value
- A nominal value assigned to a share of stock by the company that issues it, often a very small amount. (The common stock of Grace Therapeutics, Inc. has a par value of $0.0001 per share, which is a nominal accounting value and not indicative of market price.)
- Nasdaq Stock Market
- A global electronic marketplace for buying and selling securities, known for listing technology and growth-oriented companies. (This is the exchange where Grace Therapeutics, Inc.'s common stock (GRCE) is traded, providing liquidity and a platform for investors.)
- Interactive Data File (Rule 405 of Regulation S-T)
- Electronic files submitted to the SEC in a standardized format (XBRL) that allows for automated processing and analysis of financial data. (Grace Therapeutics, Inc. has confirmed electronic submission of these files, indicating compliance with modern SEC digital reporting standards.)
Year-Over-Year Comparison
This filing represents the annual report for the fiscal year ended March 31, 2025. As specific financial figures and comparative data are not detailed in the provided excerpt, a direct comparison to the previous year's filing regarding revenue growth, margin changes, or newly identified risks cannot be made. The filing confirms Grace Therapeutics, Inc.'s status as a non-accelerated filer and smaller reporting company, which may or may not be a change from its previous reporting classification.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on June 23, 2025 regarding Grace Therapeutics, Inc. (GRCE).